



저작자표시-비영리-변경금지 2.0 대한민국

이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게

- 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다.

다음과 같은 조건을 따라야 합니다:



저작자표시. 귀하는 원저작자를 표시하여야 합니다.



비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다.



변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다.

- 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건을 명확하게 나타내어야 합니다.
- 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다.

저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다.

이것은 [이용허락규약\(Legal Code\)](#)을 이해하기 쉽게 요약한 것입니다.

[Disclaimer](#)

의학박사 학위논문

위암에서 헬리코박터 파일로리 제균치  
료에 의한 cIAP2 발현의 하향 조절

*Helicobacter pylori* eradication  
down-regulates cellular inhibitor  
of apoptosis protein 2 in gastric  
carcinogenesis

2016년 8월

서울대학교 대학원

의학과 내과학

윤 혁

# 위암에서 헬리코박터 파일로리 제균치 료에 의한 cIAP2 발현의 하향 조절

*Helicobacter pylori* eradication down-regulates  
cellular inhibitor of apoptosis protein 2 in  
gastric carcinogenesis

지도교수 정 현 채

이 논문을 의학박사 학위논문으로 제출함.

2016년 4월

서울대학교 대학원

의학과 내과학

윤 혁

내과학의 의학박사 학위논문을 인준함.

2016년 6월

위 원 장 \_\_\_\_\_ (인)

부위원장 \_\_\_\_\_ (인)

위 원 \_\_\_\_\_ (인)

위 원 \_\_\_\_\_ (인)

위 원 \_\_\_\_\_ (인)

## Abstract

# *Helicobacter pylori* eradication down-regulates cellular inhibitor of apoptosis protein 2 in gastric carcinogenesis

Hyuk Yoon  
Internal Medicine  
The Graduate School  
Seoul National University College of Medicine

**Background:** To evaluate the expression of cellular inhibitor of apoptosis protein 2 (*cIAP2*) during gastric carcinogenesis after *Helicobacter pylori* (HP) infection and after HP eradication

**Methods:** We divided non-cancer patients into 4 groups according to the status of HP infection and atrophic gastritis (AG)/intestinal metaplasia (IM); we compared *cIAP2* mRNA expression among these 4 groups and patients with HP-positive early gastric cancer (EGC) by real-time PCR. We evaluated the expression of *cIAP2* mRNA/protein by real-time PCR/immunohistochemistry, and the degree of apoptosis by TUNEL assay before and 12 months after

endoscopic submucosal dissection (ESD) in HP-positive EGC patients irrespective of whether they received eradication therapy.

**Results:** The expression of *cIAP2* mRNA was significantly higher in groups with HP(+) and AG/IM(+) and HP-positive EGC than in the control, HP(+) and AG/IM(-) groups ( $p < 0.005$ ). In the HP eradication group, the expression of *cIAP2* mRNA/protein significantly decreased ( $p = 0.006$ ) and apoptosis increased at the 12-month follow-up after ESD. In the HP non-eradication group, the aforementioned changes were not found at the same follow-up period.

**Conclusion:** The expression of *cIAP2* increased during gastric carcinogenesis after HP infection; HP eradication in the patients who underwent ESD for EGC reversed the over-expression of *cIAP2* and suppressed cell apoptosis.

**Keywords:** *Helicobacter pylori*, cellular inhibitor of apoptosis protein 2, gastric carcinogenesis

**Student Number :** 2012-30516

# Contents

Abstract .....	i
Contents .....	iii
List of figures .....	iv
List of abbreviations .....	v
Introduction .....	1
Materials and Methods .....	3
Results .....	12
Discussion .....	19
References.....	23
국문초록 .....	28

## List of Figures

**Figure 1.** Heat map of the Human Apoptosis RT2 Profiler™ PCR Array

**Figure 2.** Expression of *cIAP2* mRNA by real-time PCR in 5 groups classified according to the status of *Helicobacter pylori* infection, atrophic gastritis/intestinal metaplasia, and gastric cancer

**Figure 3.** The expression of *cIAP2* mRNA by real-time PCR in patients with *Helicobacter pylori*-positive early gastric cancer before endoscopic submucosal dissection and at the 12-month follow-up

**Figure 4.** Representative immunohistochemical staining for *cIAP2* protein in patients with *Helicobacter pylori*-positive early gastric cancer before and 12 months after endoscopic submucosal dissection (original magnification ×200)

**Figure 5.** Representative terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) staining of gastric tissues from patients with *Helicobacter pylori*-positive early gastric cancer before endoscopic submucosal dissection and at the 12-month follow-up (original magnification ×200)

# List of Abbreviations

AG: atrophic gastritis

cIAP2: cellular inhibitor of apoptosis protein 2

EGC: early gastric cancer

EGD: esophagogastroduodenoscopy

ESD: endoscopic submucosal dissection

*H. pylori* : *Helicobacter pylori*

IAP: Inhibitor of apoptosis protein

IHC: immunohistochemistry

IM: intestinal metaplasia

NF- $\kappa$ B: nuclear factor- $\kappa$ B

TUNEL: terminal deoxynucleotidyl transferase-mediated nick end labeling

## Introduction

Inhibitor of apoptosis protein (IAP) is defined as a protein containing one or more repeats of the baculovirus IAP domain.<sup>1</sup> IAP is one of the major proteins controlling apoptosis, which plays an important role in both normal development and diseases. Until now, 8 types of IAP family proteins have been identified. Among these, cellular inhibitor of apoptosis protein 2 (*cIAP2*) is known to play an important role in carcinogenesis.<sup>2</sup> *cIAP2* is induced by nuclear factor- $\kappa$ B (NF- $\kappa$ B),<sup>3</sup> and is reported to inhibit apoptosis by down-regulating certain caspases.<sup>4</sup> Overexpression of *cIAP2* has been reported in colon and pancreatic cancer.<sup>5, 6</sup> However, studies investigating the role of *cIAP2* in gastric carcinogenesis are scarce.

Causing an imbalance between cell proliferation and apoptosis is one of several mechanisms through which *Helicobacter pylori* (*H. pylori*) induces gastric cancer.<sup>7, 8</sup> *H. pylori* is known to either activate or inhibit apoptosis depending on the degree, duration, and nature of infection. For example, *H. pylori* expressing *CagA* and *VacA* stimulates apoptosis in gastric epithelial cells.<sup>9</sup> Pro-apoptotic genes were overexpressed in *H. pylori*-infected patients,<sup>10</sup> and apoptosis increased in the early stage of gastric carcinogenesis due to *H. pylori* infection.<sup>11</sup> Conversely, it was also reported that *H. pylori* can inhibit apoptosis. It is known that *H. pylori* activates NF-

$\kappa$ B in a *Cag* pathogenicity island-dependent manner and subsequently induces the up-regulation of *cIAP2* expression.<sup>7, 12</sup> Expression of both NF- $\kappa$ B and *cIAP2* increased when gastric cancer cell lines were co-cultured with *CagA*-positive *H. pylori*.<sup>12</sup> Conversely, knockdown of *cIAP2* in gastric cancer cell lines resulted in increased apoptosis, decreased cell proliferation, and delayed cell migration.<sup>13</sup> In mouse models, *H. pylori* infection induced increased *cIAP2* in the gastric mucosa.<sup>13</sup> Finally, *cIAP2* was reportedly overexpressed in more than 70% of human gastric cancer tissues;<sup>13</sup> overexpression was more prominent in cancer tissues than in adjacent non-cancer tissues, and in *H. pylori*-positive patients than in *H. pylori*-negative patients.<sup>14</sup> Therefore, it was suggested that *cIAP2* overexpression plays an important role in *H. pylori*-induced gastric carcinogenesis. However, the exact stage at which overexpression of *cIAP2* commences during progression from *H. pylori* infection to gastric cancer is unclear.

The first aim of this study was to evaluate *cIAP2* overexpression during human gastric carcinogenesis after *H. pylori* infection in the context of atrophic gastritis (AG) and intestinal metaplasia (IM). The second aim was to determine whether eradication of *H. pylori* in patients who underwent endoscopic submucosal dissection (ESD) for early gastric cancer (EGC) reverses *cIAP2* overexpression.

# Materials and Methods

## 1. Subjects and study design

This study was carried out in three stages. First, we determined the expression of several IAP family genes, including *cIAP2*, in the gastric mucosal samples of control subjects who were *H. pylori*-negative and showed no evidence of AG and IM in either the antrum or the body, and in patients with *H. pylori*-positive EGC (2 samples in each group). In the second step, we divided non-cancer patients into 4 groups according to the presence or absence of *H. pylori* infection and AG/IM, and we compared the expression of *cIAP2* mRNA among them as well as among *H. pylori*-positive EGC patients by real-time PCR (22 samples in each group). Lastly, we evaluated the expression of *cIAP2* mRNA/protein and the degree of apoptosis before and 12 months after ESD in *H. pylori*-positive EGC patients irrespective of whether they received eradication therapy (eradication group: n = 12, non-eradication group: n = 15). In this stage, the expression levels of *cIAP2* protein and the degree of apoptosis were analyzed by immunohistochemistry (IHC) and terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) assay, respectively (3 representative samples in each group).

In the present study, gastric tissues of patients without EGC were acquired from subjects who underwent esophagogastroduodenoscopy (EGD) and were healthy or diagnosed with gastritis between October 2005 and October 2006. Gastric tissues of EGC patients were acquired from samples that were previously collected for another study; the summary of that study is as follows.<sup>15</sup> *H. pylori*-positive patients who underwent ESD for EGC were randomly assigned into eradication or non-eradication group. Patients in the eradication group received 20 mg omeprazole, 1 g amoxicillin, and 500 mg clarithromycin twice daily for 1 week. Patients in the non-eradication group received no antibiotics. All patients underwent follow-up EGD regularly for several years. Successful eradication was confirmed in the eradication group by both histologic evaluation and rapid urease test. The primary outcome was development of metachronous gastric carcinoma. We used some samples from that study to evaluate the effect of *H. pylori* eradication on cIAP2 expression and apoptosis in the EGC patients before and 12 months after ESD. This study was approved by the Institutional Review Board of Seoul National University Hospital (IRB number: H-1205-016-408).

## 2. Gastric tissue collection

We collected 2 sections of gastric mucosal tissue from the lesser curvature of the antrum and body by endoscopic biopsy from all subjects; in patients with EGC, non-cancerous tissues were collected. *H. pylori* infection status was determined by histologic evaluation and the rapid urease test, which was performed in another tissue sample from the lesser curvature of the antrum. *H. pylori* infection was deemed positive if at least one of two tests was positive. The degree of AG and IM in the gastric mucosa was classified according to the updated Sydney system.<sup>16</sup> Negative AG/IM was defined as no evidence of AG and IM in both the antrum and body. Positive AG/IM was defined as moderate or high AG or IM in either the antrum or body.

## 3. Real-time PCR microarray for IAP family genes

We collected 4 samples each from control subjects who were *H. pylori*-negative and showed no AG and IM, and from subjects with *H. pylori*-positive EGC. We then extracted the total RNA and performed quality control tests; 2 samples from each group were selected. Briefly, total RNA was extracted using the RNeasy midi kit (Qiagen, Hilden, Germany) according to the manufacturer's

instructions and treated with RNase-free DNase I (Promega, Madison, WI, USA) to reduce DNA contamination. Total RNA concentration and purity were determined by measuring the 260:280 nm absorbance ratio using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The integrity of RNA samples was confirmed by the appearance of distinct 28S and 18S bands of ribosomal RNA using a Bioanalyzer 2100 system (Agilent Technology, Santa Clara, CA, USA).

We then analyzed mRNA expression of several IAP family genes including *cIAP2* by real-time PCR microarray. Briefly, cDNA was synthesized from 1  $\mu$ g total RNA according to the manufacturer's instructions (RT2 First Strand kit; Qiagen). For quantitative comparison of mRNA levels, real-time PCR was performed using Human Apoptosis RT<sup>2</sup> Profiler™ PCR Array (QIAGEN Korea Ltd, South Korea). This real-time PCR microarray consisted of a 96-well plate and included 84 genes closely related to apoptosis and cell survival, in addition to positive/negative controls. Two independent assays were performed for each condition. Gene expression was measured relative to the mean expression of  $\beta$ -actin as the endogenous control. Reactions were carried out on a StepOnePlus™ Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). Real-time PCR detection was performed

under the following thermal cycling conditions: 95° C for 10 min, then 40 cycles of 95° C for 15 s and 60° C for 1 min. For analysis using the  $\Delta\Delta C_t$  method, we used the PCR Array Data Analysis Software (SaBiosciences; <http://www.qiagen.com/kr/products/genes%20and%20pathways/data-analysis-center-overview-page/>).

#### 4. Real-time PCR for *cIAP2* mRNA

Gastric mucosal specimens for real-time PCR were collected from the lesser curvature of the antrum. Total RNA was extracted from the specimens using Trizol Reagent (Invitrogen, Carlsbad, CA, USA) per manufacturer's instructions and purified using RNeasy mini kits (Qiagen, Valencia, CA, USA).<sup>17</sup> RNA samples were then treated with DNase I (Invitrogen) and quantified by spectrophotometry. Total RNA was amplified and then labeled in the presence of fluorescent dNTP (Cy3 dUTP or Cy5 dUTP; GE Healthcare, Piscataway, NJ, USA). RNA samples were diluted to a final concentration of 0.5 mg/mL in RNase-free water and stored at -80° C until use. cDNA synthesis was performed with 1 mg of total RNA with M-MLV reverse transcription reagents (Invitrogen), and real-time PCR was conducted using the ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) in

20  $\mu$ L TaqMan Gene Expression Master Mix (Applied Biosystems) using 200 ng cDNA. The primary sequences used for *cIAP2* were as follows: forward, 5' -TCCTAGCTGCAGATTCGTTC-3' ; reverse, 5' -CAAAGCAAGCCACTCTGTCT-3' for a 349 bp PCR product. The primary sequences of GAPDH, which was used for the internal control, were as follows: forward, 5' -GCTCTCTGCTCCTCCTGTTC-3' ; reverse, 5' -CGACCAAATCCGTTGACTCC-3' for a 114 bp PCR product. The reaction conditions were 50° C for 2 min, 95° C for 10 min, followed by 40 cycles of 95° C for 15 s and 60° C for 1 min. The human GAPDH gene was used as an endogenous reference when calculating Ct values. Relative gene expression values were determined from the Ct values using the  $2^{-\Delta\Delta Ct}$  method.<sup>18</sup>

## 5. Immunohistochemistry for *cIAP2* protein

Tissues from the antrum were fixed in 10% neutral buffered formalin, paraffin-embedded, and then cut into 4- $\mu$ m sections. Slides were stained using the Discovery XT automated immunohistochemistry stainer (Ventana Medical Systems, Inc., Tucson, AZ, USA) and detection was performed using the Ventana Chromo Map Kit (Ventana Medical Systems). Sections were deparaffinized using the EZ Prep solution. CC1 (pH 8.4 buffer

containing Tris/Borate/EDTA) was used for antigen retrieval. Endogenous peroxidases were blocked with Inhibitor D (3% H<sub>2</sub>O<sub>2</sub>) for 4 min at 37° C temperature. Slides were incubated with primary antibodies for 32 min at 37° C and a secondary antibody for 20 min at 37° C. Slides were incubated in diaminobenzidine (DAB) plus H<sub>2</sub>O<sub>2</sub> substrate for 8 min at 37° C followed by hematoxylin and bluing reagent counterstain at 37° C. Reaction buffer (pH 7.6 Tris buffer) was used as a washing solution. A monoclonal antibody for cIAP2 (Santa Cruz Biotechnology; Santa Cruz, CA, USA; dilution 1:30) was used as a primary antibody, and biotin-labeled anti-mouse immunoglobulin G (UltraMap anti-Ms HRP Roche, Ventana Medical Systems, Inc., Tucson, AZ, USA) was used as a secondary antibody. Negative controls were treated similarly while excluding the primary antibodies. The whole slide area was assessed and positive staining was qualitatively evaluated by an experienced pathologist (ES).

## **6. Terminal deoxynucleotidyl transferase-mediated nick end labeling assay**

To evaluate apoptosis, TUNEL staining was performed using the Apoptag<sup>®</sup> Peroxidase In Situ Apoptosis Detection Kit S7100

(Millipore Corporation, Billerica, USA).<sup>19</sup> After deparaffinization with xylene and graded concentrations of alcohol, gastric mucosal tissue sections were exposed to Proteinase K for 15 min at room temperature. Endogenous peroxidase activity was quenched with Inhibitor D for 5 min at room temperature. Sections were incubated with terminal deoxynucleotidyl transferase (TdT) in a humidified chamber at 37° C for 1 h. After incubation with anti-digoxigenin-conjugate for 30 min at room temperature, peroxidase substrate and 0.05% DAB was applied to develop color. The specimens were then washed with distilled water and counterstained with 0.5% methyl green for 10 min at room temperature. Sections were counterstained with Mayer's hematoxylin. Identically-treated slides not exposed to TdT served as negative controls. In all cases, positive staining was qualitatively evaluated on the entire slide by an experienced pathologist (ES).

## **7. Statistical analysis**

SPSS for Windows (version 18.0; SPSS, Chicago, IL, USA) was used for statistical analysis. Because the data were not normally distributed (as demonstrated by the Shapiro-Wilk test), the relative expression of *cIAP2* mRNA among several

groups was compared using a Kruskal–Wallis test. Post hoc comparisons of pairwise differences between two groups were evaluated by the Mann–Whitney U test using the modified Bonferroni procedure for multiple comparison adjustment. To compare the expression levels of *cIAP2* mRNA in *H. pylori*–positive EGC before and at 12–months after ESD, a Wilcoxon signed–rank test was performed. Results with *P*–values less than 0.05 were considered significant.

# Results

## 1. Real-time PCR microarray for IAP family genes

Fig. 1 shows the heat map of PCR microarray. Among the 5 IAP family genes analyzed (*Survive*, *cIAP1*, *cIAP2*, *XIAP*, *NAIP*), only the *cIAP2* (BIRC3) mRNA was 1.85 times higher in subjects with *H. pylori*-positive EGC than in *H. pylori*-negative controls without AG/IM.

Fig. 1




Figure 1. Heat map of the Human Apoptosis RT<sup>2</sup> Profiler™ PCR Array

The gene symbol, value of  $\log^2$  fold change of mRNA expression, and reliability of the data are presented on the bottom. OKAY, A, and B indicate good, moderate, and poor data reliability, respectively. In the top grid, the magnitude of  $\log^2$  fold change of mRNA expression of each gene is represented by the color of each square. Red indicates mRNA overexpression while green indicates reduced mRNA expression.

\* Among the 5 IAP family genes analyzed (*Survive*, *cIAP1*, *cIAP2*, *XIAP*, *NAIP*), the expression of only *cIAP2* (BIRC3) mRNA was increased 1.85 times in subjects with *H. pylori*-positive EGC (n = 2) compared to the expression in *H. pylori*-negative controls without atrophic gastritis or intestinal metaplasia (n = 2) (row C, column 09).

## 2. Real-time PCR for *cIAP2* mRNA

We performed *cIAP2* mRNA real-time PCR for 22 samples in each group. However, the results of several samples were not interpretable, and were thus excluded. Therefore, the number of samples in each group varied, ranging between 18 and 22 (normal control, both *H. pylori* and AG/IM-positive group, *H. pylori*-positive EGC: n = 22, *H. pylori*-positive and AG/IM-negative group: n = 18, *H. pylori*-negative and AG/IM-positive group: n = 20). Fig. 2 shows the expression levels of *cIAP2* mRNA in gastric mucosal tissues by real-time PCR. There was a significant difference in the relative expression of *cIAP* mRNA among the 5 groups ( $p < 0.001$ ). Post-hoc analysis showed that the expression of *cIAP2* mRNA was significantly higher in patients positive for both

*H. pylori* and AG/IM as well as in *H. pylori*-positive EGC patients than in control patients and those positive for *H. pylori* but negative for AG/IM ( $p < 0.005$ ).

Fig. 2




Figure 2. Expression of *cIAP2* mRNA by real-time PCR in 5 groups classified according to the status of *Helicobacter pylori* infection, atrophic gastritis/intestinal metaplasia, and gastric cancer

(a) Normal control, (b) HP (+) and AG/IM (-), (c) HP (-) and AG/IM (+), (d) HP (+) and AG/IM (+), (e) HP-positive EGC. HP; *Helicobacter pylori*, AG; atrophic gastritis, IM; intestinal metaplasia, EGC: early gastric cancer.

There was a significant difference in the relative expression of *cIAP* mRNA among the 5 groups ( $p < 0.001$ ). \*Post-hoc analysis showed that the expression of *cIAP2* was significantly higher in groups with HP(+) and AG/IM (+) (d) and HP-positive EGC (e) than in the controls (a) ( $p < 0.005$ ).

### 3. Effect of *H. pylori* eradication on *cIAP2* expression and apoptosis

The effect *H. pylori* eradication on *cIAP2* expression and apoptosis in the EGC patients after ESD was evaluated in 27 subjects (eradication group:  $n = 12$ , non-eradication group:  $n = 15$ ). Fig. 3 shows the expression of *cIAP2* mRNA by real-time PCR in patients with *H. pylori*-positive EGC before ESD and at 12 months following the procedure. The *cIAP2* mRNA levels before ESD were not significantly different between the eradication and non-eradication groups ( $p = 0.354$ ). In the eradication group, the expression levels of *cIAP2* mRNA had decreased significantly after 12-months ( $p = 0.006$ ) (Fig. 3a). In the non-eradication group, however, there was no difference in the expression of *cIAP2* mRNA before and 12 months after ESD ( $p = 0.14$ ) (Fig. 3b). Fig. 4 shows representative IHC staining for *cIAP2* protein in patients with *H. pylori*-positive EGC before ESD and at 12 months following the procedure. In the eradication group, the expression of *cIAP2* protein decreased at the 12-month follow-up time (Fig. 4b). In the non-eradication group, there was no difference in the expression of *cIAP2* protein before ESD and 12 months after (Fig. 4d). Fig. 5 shows representative TUNEL staining in patients with *H. pylori*-positive EGC before and at 12 months after ESD. In the eradication group, cell apoptosis had increased 12 months following the ESD procedure (Fig. 5b). In the non-eradication group, there was no difference in cell apoptosis before and 12 months after ESD (Fig. 5d).

Fig. 3




Figure 3. The expression of *cIAP2* mRNA by real-time PCR in patients with *Helicobacter pylori*-positive early gastric cancer before endoscopic submucosal dissection and at the 12-month follow-up: (a) Eradication group (n = 12), (b) Non-eradication group (n = 15).

In the eradication group, the expression of *cIAP2* mRNA decreased significantly at the 12-month follow-up time ( $p = 0.006$ ). In the non-eradication group, there was no difference in the expression of *cIAP2* mRNA before and 12 months after endoscopic submucosal dissection ( $p = 0.14$ ).

Fig. 4




Figure 4. Representative immunohistochemical staining for *cIAP2* protein in patients with *Helicobacter pylori*-positive early gastric cancer before and 12 months after endoscopic submucosal dissection (n = 3 for each group) (original magnification  $\times 200$ )

(a) Strong expression of *cIAP2* in the eradication group before endoscopic submucosal dissection (ESD), (b) Faint expression of *cIAP2* in the eradication group at the 12-month follow-up, (c) Strong expression of *cIAP2* in the non-eradication group before ESD, (d) Strong expression of *cIAP2* in the non-eradication group at the 12-month follow-up

In the eradication group, the expression of *cIAP2* protein decreased at 12-month follow-up. In the non-eradication group, there was no difference in *cIAP2* protein expression before and 12 months following ESD.

Fig. 5




Figure 5. Representative terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) staining of gastric tissues from patients with *Helicobacter pylori*-positive early gastric cancer before endoscopic submucosal dissection and at the 12-month follow-up (n = 3 for each group) (original magnification  $\times 200$ )

a) Eradication group before endoscopic submucosal dissection (ESD), (b) Eradication group at the 12-month follow-up, (c) Non-eradication group before ESD, (d) Non-eradication group at the 12-month follow-up

In the eradication group, cell apoptosis assayed by TUNEL increased at the 12-month follow-up. In the non-eradication group, there was no difference in cell apoptosis before ESD and at the 12-month follow-up.

## Discussion

Previous investigations of the relationship between *H. pylori* infection and *cIAP2* expression during gastric carcinogenesis were performed in gastric cancer cell lines co-cultured with *H. pylori*<sup>7, 12</sup> or in a mouse model of *H. pylori* infection.<sup>13</sup> In this study, we explored the role of *cIAP2* in *H. pylori*-induced gastric carcinogenesis in humans. We found that overexpression of *cIAP2* during gastric carcinogenesis requires not only *H. pylori* infection, but also progression to AG/IM. These results are consistent with previous reports showing that *H. pylori* has both apoptotic and anti-apoptotic effects.<sup>7</sup> When *H. pylori* infection becomes chronic, anti-apoptotic signaling pathways becomes predominant.<sup>14</sup> Moreover, the expression of *cIAP2* mRNA mildly decreased in patients with negative *H. pylori* infection and positive AG/IM compared to control patients. This indicates that progression of AG/IM is not sufficient to induce overexpression of *cIAP2* mRNA in gastric carcinogenesis; *H. pylori* infection is also required. Although we could not perform additional experiments to clarify the link connecting *H. pylori* infection, AG/IM, and expression of *cIAP2*, we postulate that activation of NF- $\kappa$ B by *CagA* may be the primary mechanism for the development of *H. pylori*-specific gastric carcinogenesis.

Several studies reported that eradication of *H. pylori* after ESD in

patients with EGC decreases the incidence of metachronous gastric cancer.<sup>20–22</sup> However, the underlying molecular mechanism has not been widely explored. Tsai *et al.* reported that several genes related to cell proliferation were down-regulated in the gastric mucosa 1 year after *H. pylori* eradication.<sup>23</sup> In the present study, we found that *cIAP2* overexpression and apoptosis suppression could be reversed within 1 year after *H. pylori* eradication in patients who underwent ESD for EGC. Taken together, our results suggest that risk reduction of metachronous gastric cancer by *H. pylori* eradication after ESD in EGC patients may be related to changes in the expression of genes controlling cell proliferation and apoptosis.

There are two distinct apoptotic pathways: a death receptor (extrinsic) pathway and a mitochondrial (intrinsic) pathway.<sup>24</sup> Some reports claim that overexpression of *cIAP2* inhibits apoptosis through the suppression of caspase 3, 7, and 9 activity.<sup>25, 26</sup> Others suggest that the underlying mechanism involves the suppression of caspase 8 activity.<sup>4</sup> In this study, several caspase genes were probed with a real-time PCR microarray. We found that caspases 3, 8, and 9 were suppressed but caspase 7 was slightly over-expressed in subjects with *H. pylori*-positive EGC compared to that in *H. pylori*-negative individuals without AG/IM. These findings were somewhat counterintuitive. Moreover, *Bcl2* and *Bax*, which

play opposing roles in the intrinsic pathway, were equally overexpressed in *H. pylori*-positive EGC patients. Because we examined the expression of general apoptosis-related genes in a very limited number of samples, and the interactions of the intrinsic and extrinsic apoptosis pathways are complex, we could not determine whether *Bax* was overexpressed to counteract the overexpression of *Bcl2*. Further experiments are required to expose the pathways key to *H. pylori*-infected and *cIAP2*-induced gastric carcinogenesis.

This study had several limitations. First, we did not determine the status of *CagA* in the *H. pylori* strains in our study; hence, it was not possible to ascertain whether only *CagA*-positive *H. pylori* induces *cIAP2* overexpression during gastric carcinogenesis. Moreover, lack of assessment of other virulent factors such as *VacA* and *OipA*, which are frequently found in Asian strains, is also a limitation.<sup>27</sup> Second, because there was a limit to the number of available tissues from non-cancerous subjects, we could not evaluate the effects of AG and IM on the expression of *cIAP2* separately. Although evidence suggested that *cIAP2* was overexpressed at a relatively late stage during *H. pylori*-induced gastric carcinogenesis, the specific stage at which *cIAP2* is overexpressed remains unknown. Finally, we did not examine more

potent anti-apoptotic factors such as *Bcl2*-family member *Mcl1*.<sup>28</sup> We also did not evaluate the status of TNF-related apoptosis-inducing ligand signaling and *cIAP2*-counteracting molecules such as *Smac/DIABLO* and *Omi/Htr2A*.<sup>29</sup> Therefore, it remains uncertain whether *H. pylori* eradication-mediated *cIAP2* down-regulation alone induces apoptosis in the eradication group, as other signaling events may be involved.

In conclusion, the expression of *cIAP2* increased during gastric carcinogenesis after *H. pylori* infection and progression to AG/IM, and eradication of *H. pylori* in the patients who underwent ESD for EGC reversed the overexpression of *cIAP2* and suppressed cell apoptosis.

## References

1. Nachmias B, Ashhab Y, Ben-Yehuda D. The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. *Semin Cancer Biol* 2004;14:231–243.
2. Tamm I, Kornblau SM, Segall H, et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. *Clin Cancer Res* 2000;6:1796–1803.
3. Conte D, Holcik M, Lefebvre CA, et al. Inhibitor of apoptosis protein cIAP2 is essential for lipopolysaccharide-induced macrophage survival. *Mol Cell Biol* 2006;26:699–708.
4. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS, Jr. NF- $\kappa$ B antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. *Science* 1998;281:1680–1683.
5. Miura K, Karasawa H, Sasaki I. cIAP2 as a therapeutic target in colorectal cancer and other malignancies. *Expert Opin Ther Targets* 2009;13:1333–1345.
6. Esposito I, Kleeff J, Abiatari I, et al. Overexpression of cellular inhibitor of apoptosis protein 2 is an early event in the progression of pancreatic cancer. *J Clin Pathol* 2007;60:885–895.

7. Maeda S, Yoshida H, Mitsuno Y, et al. Analysis of apoptotic and antiapoptotic signalling pathways induced by *Helicobacter pylori*. Gut 2002;50:771–778.
8. Gupta RA, Polk DB, Krishna U, et al. Activation of peroxisome proliferator–activated receptor gamma suppresses nuclear factor kappa B–mediated apoptosis induced by *Helicobacter pylori* in gastric epithelial cells. J Biol Chem 2001;276:31059–31066.
9. Liu W, Chen Y, Lu G, Sun L, Si J. Down–regulation of HSP70 sensitizes gastric epithelial cells to apoptosis and growth retardation triggered by *H. pylori*. BMC Gastroenterol 2011;11:146.
10. Mannick EE, Schurr JR, Zapata A, et al. Gene expression in gastric biopsies from patients infected with *Helicobacter pylori*. Scand J Gastroenterol 2004;39:1192–1200.
11. Valenzuela M, Bravo D, Canales J, et al. *Helicobacter pylori*–induced loss of survivin and gastric cell viability is attributable to secreted bacterial gamma–glutamyl transpeptidase activity. J Infect Dis 2013;208:1131–1141.
12. Yanai A, Hirata Y, Mitsuno Y, et al. *Helicobacter pylori* induces antiapoptosis through nuclear factor–kappaB activation. J Infect Dis 2003;188:1741–1751.

13. Li Z, Chen J, Chan KW, Qiao L, Wong BC. A possible role of cIAP2 in *Helicobacter pylori*-associated gastric cancer. *Cancer Lett* 2011;313:192-200.
14. Chang CS, Chen WN, Lin HH, Wu CC, Wang CJ. Increased oxidative DNA damage, inducible nitric oxide synthase, nuclear factor kappaB expression and enhanced antiapoptosis-related proteins in *Helicobacter pylori*-infected non-cardiac gastric adenocarcinoma. *World J Gastroenterol* 2004;10:2232-2240.
15. Choi J, Kim SG, Yoon H, et al. Eradication of *Helicobacter pylori* after endoscopic resection of gastric tumors does not reduce incidence of metachronous gastric carcinoma. *Clin Gastroenterol Hepatol* 2014;12:793-800.
16. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. *Am J Surg Pathol* 1996;20:1161-1181.
17. Kang JM, Lee BH, Kim N, et al. CDX1 and CDX2 expression in intestinal metaplasia, dysplasia and gastric cancer. *J Korean Med Sci* 2011;26:647-653.
18. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 2001;25:402-408.

19. Park HP, Jeong EJ, Kim MH, et al. Effects of sevoflurane on neuronal cell damage after severe cerebral ischemia in rats. *Korean J Anesthesiol* 2011;61:327–331.
20. Uemura N, Mukai T, Okamoto S, et al. Effect of *Helicobacter pylori* eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. *Cancer Epidemiol Biomarkers Prev* 1997;6:639–642.
21. Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of *Helicobacter pylori* on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. *Lancet* 2008;372:392–397.
22. Kim YI, Choi IJ, Kook MC, et al. The association between *Helicobacter pylori* status and incidence of metachronous gastric cancer after endoscopic resection of early gastric cancer. *Helicobacter* 2014;19:194–201.
23. Tsai CJ, Herrera-Goepfert R, Tibshirani RJ, et al. Changes of gene expression in gastric preneoplasia following *Helicobacter pylori* eradication therapy. *Cancer Epidemiol Biomarkers Prev* 2006;15:272–280.
24. Burz C, Berindan-Neagoe I, Balacescu O, Irimie A. Apoptosis in cancer: key molecular signaling pathways and therapy targets.

- Acta Oncol 2009;48:811–821.
25. Roy N, Deveraux QL, Takahashi R, Salvesen GS, Reed JC. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J 1997;16:6914–6925.
  26. Deveraux QL, Roy N, Stennicke HR, et al. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 1998;17:2215–2223.
  27. Kim JY, Kim N, Nam RH, et al. Association of polymorphisms in virulence factor of *Helicobacter pylori* and gastroduodenal diseases in South Korea. J Gastroenterol Hepatol 2014;29:984–991.
  28. Ricci MS, Kim SH, Ogi K, et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 2007;12:66–80.
  29. Smolewski P, Robak T. Inhibitors of apoptosis proteins (IAPs) as potential molecular targets for therapy of hematological malignancies. Curr Mol Med 2011;11:633–649.

## 국문 초록

# 위암에서 헬리코박터 파일로리 제균치료에 의한 cIAP2 발현의 하향 조절

**배경:** 본 연구에서는 위암발생과정에서 헬리코박터 파일로리 감염과 제균 이후의 cellular inhibitor of apoptosis protein 2 (cIAP2) 발현 정도를 평가해보고자 하였다.

**방법:** 위암이 아닌 환자를 헬리코박터 파일로리 감염 유무와 위축성위염/장상피화생 유무에 따라 네 군으로 나뉘, cIAP2 mRNA의 발현 정도를 이들 네 군과 헬리코박터 파일로리 양성 조기위암환자에서 real-time PCR을 통해 비교하였다. 또한 조기위암에 대해 내시경점막하박리술을 시행 받은 환자를 제균한 군과 그렇지 않은 군으로 나누어, 시술 전과 시술 12개월 뒤의 cIAP2 mRNA와 단백질 발현 정도를 각각 real-time PCR과 면역조직화학을 통해, 세포자멸사 정도를 TUNEL assay를 통해 비교하였다.

**결과:** 정상대조군과 헬리코박터 파일로리 양성이나 위축성위염/장상피화생이 없는 군에 비해 헬리코박터 파일로리 양성이며 위축성위염/장상피화생이 있는 군과 헬리코박터 파일로리 양성 조기위암 군에서는 cIAP2 mRNA의 발현이 유의하게 증가되어 있었다 ( $p < 0.005$ ). 조기위암에 대해 내시경점막하박리술 후 제균치료를 시행한

군에서는 cIAP2 mRNA와 단백질 발현이 시술 전에 비해 시술 12개월 뒤에 유의미하게 감소되어 있었으며 ( $p = 0.006$ ) 세포자멸사 정도는 반대로 증가하였다. 제균치료를 시행하지 않은 군에서는 상기와 같은 소견이 관찰되지 않았다.

**결론:** 헬리코박터 파일로리 감염 이후 위암발생과정에서 cIAP2의 발현은 증가되어 있었으며, 조기위암에 대해 내시경점막하박리술을 시행 받은 환자에서 헬리코박터 파일로리 제균치료는 이러한 cIAP2의 과발현과 억제된 세포자멸사를 정상화시켰다.

**주요어 :** *Helicobacter pylori*, cellular inhibitor of apoptosis protein 2, gastric carcinogenesis

**학번 :** 2012-30516